Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adaptimmune Therapeutics plc    ADAP

ADAPTIMMUNE THERAPEUTICS PLC

(ADAP)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2020 11/25/2020 11/27/2020 11/30/2020 12/01/2020 Date
4.37(c) 4.61(c) 4.91(c) 5.01(c) 4.75(c) Last
1 500 472 1 293 415 1 224 704 2 565 217 2 971 504 Volume
-3.96% +5.49% +6.51% +2.04% -5.19% Change
More quotes
Financials (USD)
Sales 2020 3,22 M - -
Net income 2020 -131 M - -
Net Debt 2020 - - -
P/E ratio 2020 -5,14x
Yield 2020 -
Sales 2021 3,78 M - -
Net income 2021 -170 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,24x
Yield 2021 -
Capitalization 735 M 735 M -
Capi. / Sales 2020 229x
Capi. / Sales 2021 194x
Nbr of Employees 420
Free-Float 7,27%
More Financials
Company
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its SPEAR T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (TCRs) against those targets, and produce therapeutic candidates (SPEAR T-cells) for... 
More about the company
Notations Surperformance© of Adaptimmune Therapeutics plc
Trading Rating : Investor Rating :
More Ratings
All news about ADAPTIMMUNE THERAPEUTICS PLC
11/23ADAPTIMMUNE THERAPEUTICS : to Showcase Market Potential for SPEAR T-cell Portfol..
AQ
11/20ADAPTIMMUNE THERAPEUTICS : Durable Responses with ADP-A2M4 in Synovial Sarcoma w..
AQ
11/20ADAPTIMMUNE THERAPEUTICS PLC : Regulation FD Disclosure, Financial Statements an..
AQ
11/20ADAPTIMMUNE THERAPEUTICS : to Showcase Market Potential for SPEAR T-cell Portfol..
AQ
11/20Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipel..
GL
11/19ADAPTIMMUNE THERAPEUTICS PLC : Regulation FD Disclosure, Financial Statements an..
AQ
11/19Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses ..
GL
11/19ADAPTIMMUNE THERAPEUTICS : Durable Responses with ADP-A2M4 in Synovial Sarcoma w..
AQ
11/13ADAPTIMMUNE THERAPEUTICS : to Host Virtual Investor Day on Friday, November 20th
AQ
11/12ADAPTIMMUNE THERAPEUTICS : to Host Virtual Investor Day on Friday, November 20th
AQ
11/12Adaptimmune to Host Virtual Investor Day on Friday, November 20th
GL
11/10ADAPTIMMUNE THERAPEUTICS : Elliot Norry, Chief Medical Officer – SITC 2020..
PU
11/09ADAPTIMMUNE THERAPEUTICS PLC : Regulation FD Disclosure, Financial Statements an..
AQ
11/09ADAPTIMMUNE THERAPEUTICS : Two Confirmed Responses and Five out of Six Patients ..
AQ
11/09Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reduc..
GL
More news
News in other languages on ADAPTIMMUNE THERAPEUTICS PLC

- No features available -

More news
Analyst Recommendations on ADAPTIMMUNE THERAPEUTICS PLC
More recommendations
Chart ADAPTIMMUNE THERAPEUTICS PLC
Duration : Period :
Adaptimmune Therapeutics plc Technical Analysis Chart | ADAP | US00653A1079 | MarketScreener
Technical analysis trends ADAPTIMMUNE THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 10,60 $
Last Close Price 4,75 $
Spread / Highest target 258%
Spread / Average Target 123%
Spread / Lowest Target 26,3%
EPS Revisions
Managers
NameTitle
Adrian Rawcliffe Chief Executive Officer & Director
David M. Mott Chairman
William C. Bertrand Chief Operating Officer
Gavin Wood Chief Financial Officer
Elliot Norry Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ADAPTIMMUNE THERAPEUTICS PLC295.83%735
GILEAD SCIENCES, INC.-5.94%76 616
VERTEX PHARMACEUTICALS5.18%59 887
REGENERON PHARMACEUTICALS36.91%54 257
WUXI APPTEC CO., LTD.57.04%39 976
BIONTECH SE236.51%27 452